April 18th 2024
Cohort analysis shows the rate of RSV hospitalizations among children up to 5 years old skyrocketed in 2021—and then nearly doubled again in 2022—compared to pre-pandemic rates.
Earn CME Credits While Advancing Your Expertise in Internal Medicine
April 18-19, 2024
Register Now!
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
The Expanding Role of Fluid Biomarkers in the Diagnosis and Management of Patients With Alzheimer Disease
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis
View More
Clinical Consultations™: Considerations for Customizing Care Plans for Patients with Parkinson Disease Psychosis
View More
Advances In™ Schizophrenia: Expanding the Therapeutic Landscape
View More
Expert Illustrations & Commentaries™: Visualizing New Therapeutic Targets in Schizophrenia
View More
Respiratory Syncytial Virus: Understanding the Infection Burden and Anticipating the Impact of Vaccines
View More
(COPE Credit) Community Practice Connections™: Keeping an Eye on Evolving Management Strategies for nAMD and DME
View More
(CME Credit) Community Practice Connections™: Keeping an Eye on Evolving Management Strategies for nAMD and DME
View More
Addressing Healthcare Inequities™ in Glaucoma Management – Understanding Challenges in Segmented Patient Populations (CME Track)
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Southern California Psychiatry Conference
September 13-14, 2024
Register Now!
Cases and Conversations™: Evidence-Based Approaches to Management of CKD in Your Patients with T2DM
September 25, 2024
Register Now!
Collaborating Across the Continuum™: The Role of Multidisciplinary Care in the Management of Patients with Exocrine Pancreatic Insufficiency
View More
3rd Annual International Congress on Pediatric Oncology
October 25, 2024
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Updates on New and Emerging Therapies to Improve Outcomes for Patients With Major Depressive Disorder
View More
Patient, Provider, and Caregiver Connection™: Prevention and Control of Meningococcal Disease — Individualizing Vaccine Recommendations in Adolescent Populations
View More
5th Annual International Congress on the Future of Neurology®
View More
2023 Annual Psychiatric Times™ World CME Conference
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Advances In™ Rare Genetic Forms of Obesity: Emerging Therapeutic Targets
View More
Patient, Provider, and Caregiver Connection™: Exploring Unmet Needs In Postpartum Depression – Making the Case for Early Detection and Novel Treatments
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Comprehensive Approaches to Creating Successful Sickle Cell Management Plans Across Patients’ Lifespans
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
Addressing Healthcare Inequities: Bridging the Gap in Multiple Sclerosis – A Focus on Clinical and Healthcare Disparities in Black Patients
View More
Discussing the upcoming RSV season, new tools, and vaccine hesitancy
September 27th 2023In collaboration with Contemporary Pediatrics, Contemporary OB/GYN, and Contagion, Tina Tan, MD, FAAP, FIDSA, FPIDS, discusses the benefits of having new tools to fight RSV in infants, potential vaccine hesitancy, and RSV trends currently being observed.
CDC recommends Pfizer’s maternal RSV vaccine to protect newborns
September 25th 2023Ahead of the first fall and winter virus seasons in which vaccines are available for COVID-19, influenza, and respiratory syncytial virus (RSV), the Centers for Disease Control and Prevention is recommending Pfizer’s maternal vaccine to protect newborns from severe RSV illness.
Poll: Majority of parents concerned about bad air quality, impact on child's health
September 19th 2023According to a recent C.S. Mott Children’s Hospital National Poll on Children’s Health, the recent wildfires and extreme weather events that are creating poor or unhealthy air quality are also causing concern for parents in regards to their children's health.
CDC issues health advisory alert after increases in RSV activity
September 6th 2023Due to increased RSV activity observed in Southeastern regions of the United States, the Centers for Disease Control and Prevention (CDC) has issued an official Health Alert Network Health Advisory. The CDC recommends that clinicians prepare to implement recently FDA-approved prevention methods.
Wildfires and smoke inhalation: What are the short- and long-term effects?
August 28th 2023Donna Hallas PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN, reflects on an article about wildfire inhalation and children, published in our August 2023 issue, and provides pediatric nurse practitioners some tips if they encounter these types of cases.
FDA approves Pfizer’s maternal vaccine to prevent RSV in infants
August 21st 2023Approved for use at 32 weeks through 36 weeks gestation, Pfizer’s maternal respiratory syncytial vaccine (Abrysvo), is delivered through a single dose injection to the muscle, and is the first vaccine for use in pregnant individuals to prevent lower respiratory tract disease (LRTD) and severe LRTD because of RSV in infants (birth to 6 months).
AAP recommends all infants receive nirsevimab to fight RSV
August 15th 2023The recommendation from the American Academy of Pediatrics (AAP) follows the unanimous recommendation by the CDC advisory group for routine use of nirsevimab in newborns and infants younger than 8 months born into or entering their first RSV season.
Hybrid, AI stethoscope effective for detecting cardiac and respiratory disease
August 14th 2023Study authors stated that several past studies have put focus on training an independent model separately for lung or heart sound diagnosis but note that having a model that can “simultaneously detect abnormal lung and heart sounds,” is essential.
Nirsevimab-alip unanimously recommended by CDC advisory group to prevent RSV
August 3rd 2023The ACIP voted in unanimous fashion, 10 to 0, to recommend routine use of nirsevimab-alip for newborns and infants younger than 8 months, born during or entering the first RSV season according to a press release from Sanofi.
Combination test for COVID-19, influenza A/B, RSV receives FDA 510(k) clearance
August 3rd 2023Previously available under an Emergency Use Authorization, the combination test can detect and distinguish COVID-19, influenza A/B, and respiratory syncytial virus (RSV). The clearance comes ahead of respiratory season, which, according to BD, could result in another “tripledemic” threat.
American Indian and Alaska Native children experience high rates of RSV-related hospitalizations
July 24th 2023Results from this active, facility-based surveillance study revealed hospitalization rates for children younger than 5 years were 1.7 to 7.1 times higher among American Indian and Alaska Native children compared to estimates from the methodologically similar US New Vaccine Surveillance Network (NVSN).
Pfizer announces phase 2 data of Group B Streptococcus vaccine candidate
July 20th 2023According to Pfizer, the investigational vaccine to protect against Group B Streptococcus (GBS) generated maternal antibody responses against 6 capsular polysaccharide serotypes and efficiently transferred antibodies to the infants. The announcement of this phase 2 data comes in July, which is International Group B Streptococcus Month.
Nirsevimab-alip FDA approved to prevent RSV in neonates, infants
July 17th 2023The approval follows a unanimous vote of support from the FDA Antimicrobial Drugs Advisory Committee of nirsevimab-alip’s favorable benefit-risk profile for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants amid their first RSV season.
Nirsevimab recommended by FDA Advisory Committee to prevent RSV in infants
June 9th 2023In unanimous fashion, the FDA AMDAC voted 21 to 0 that nirsevimab has a favorable benefit risk profile for the prevention of RSV lower respiratory tract disease (LRTD) in newborns and infants during their first RSV season.
How AI can help detect and monitor coughing in infants and young children
May 31st 2023Devan Jaganath, MD, MPH, pediatric infectious disease physician, University of California San Francisco Benioff Children's Hospitals, explains how Hyfe AI and other artificial intelligence algorithms can detect and monitor coughing, potentially playing a role in treating RSV patients.
Pfizer's infant RSV vaccine receives FDA Advisory Committee's support
May 19th 2023The FDA Advisory Committee recently voted in support of approval for Pfizer's maternal immunization vaccine to help prevent RSV in infants. In this Contemporary Pediatrics® interview, Tina Tan, MD, FAAP, FIDSA, FPIDS, pediatric infectious diseases attending, Ann & Robert H. Lurie Children's Hospital, Chicago, explains what this means for this patient population ahead of an expected FDA decision in August, 2023.